Hypoxia makes chemo-radiation therapeutics less effective and renders the metastatic potential more favorable. Emerging research has found that the transcriptional expression of hypoxia-inducible factor-1alpha (HIF-1α) promotes the transcription of vascular endothelial growth factor A (VEGF-A) and Hexokinase-I (HK-I), which are associated to cellular growth, angiogenesis, and metastatic invasion in many malignancies.
In the present study, Farooq and colleagues evaluated the expression of hypoxia-associated metabolic and angiogenesis markers like HIF-1α, VEGFA, and Hexokinase-I in different sub groups of breast cancers to investigate whether anti-HIF-1 could be employed as a therapeutic target to impede the role of VEGFA and HK-I in tumor development and progression in different sub-types of breast cancer.
© enotmaks / Fotolia
Translational Medicine Communications is an interdisciplinary forum for all scientifically valid research from across translational medicine. We publish research that focuses on the biology of disease, as well as preclinical and basic research that is closely associated with medicine. Translational Medicine Communications will also consider reviews, methodology articles, protocols and commentaries.
Â
Our aim is to improve transparency and reproducibility within translational medicine, which is why we consider research papers regardless of outcome or significance of findings, as well as protocols for future research. We aim to serve the translational science community by publishing all scientifically valid and technically sound articles and we are dedicated to facilitating the communication between basic and clinical science.
Translational Medicine Communications is the companion journal to Journal of Translational Medicine.
Journal of Translational Medicine considers articles focusing on information derived from human experimentation to optimise the communication between basic and clinical science.
Dr. Marincola is Global Head of Research at Kite Pharma, Santa Monica, California. He was previously President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation; Chief Research Officer at Sidra Research, Qatar; and Tenured Investigator at the National Institutes of Health, Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine and is the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is also an award winning fiction author of The Wise Men of Pizzo and Cat Behind the Window.
2022 Speed
21 days submission to first editorial decision for all manuscripts (Median)
115 days submission to accept (Median)
2022 Usage
141,096 downloads
316 Altmetric mentions